1887

Abstract

Identification of PorA types remains important, as the PorA protein is a major immunogenic component of several meningococcal vaccines under development. In this study, 191 serogroup B isolates collected in Argentina through active laboratory-based surveillance from 2001 to 2003 were serosubtyped. Nucleotide sequences of the variable region 1 (VR1) and VR2 regions were determined in 52 non-serosubtypeable isolates. A substantial number of distinct VR types were identified, and a new VR2 variant from the P1.16 family was described. This is the first report describing PorA types in serogroup B isolates in Argentina. Furthermore, the wide diversity of subtypes detected by serosubtyping and genosubtyping reveals the difficulty in designing a useful outer-membrane vaccine applicable in this country. A possible mechanism responsible for altered PorA expression was analysed in two PorA types.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47631-0
2008-03-01
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/3/338.html?itemId=/content/journal/jmm/10.1099/jmm.0.47631-0&mimeType=html&fmt=ahah

References

  1. Abdillahi H., Poolman J. T. 1987; Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 48:367–371 [CrossRef]
    [Google Scholar]
  2. Bilukha O. O., Rosenstein N. 2005; Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54 (RR-7):1–21
    [Google Scholar]
  3. Cartwright K., Morris R., Rumke H., Fox A., Borrow R., Begg N., Richmond P., Pollman J. 1999; Immunogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17:2612–2619 [CrossRef]
    [Google Scholar]
  4. Chiavetta L., Chávez E., Ruzic A., Mollerach M., Regueira M. 2007; Surveillance of Neisseria meningitidis in Argentina, 1993–2005: distribution of serogroups, serotypes and serosubtypes isolated from invasive disease. Rev Argent Microbiol 39:21–27 (in Spanish)
    [Google Scholar]
  5. Clarke S. C., Diggle M. A., Mölling P., Unemo M., Olcén P. 2003; Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. Vaccine 21:2468–2473 [CrossRef]
    [Google Scholar]
  6. Derrick J. P., Urwin R., Suker J., Feavers I. M., Maiden M. C. 1999; Structural and evolutionary inference from molecular variation in Neisseria porins. Infect Immun 67:2406–2413
    [Google Scholar]
  7. Feavers I. M., Maiden M. C. 1998; A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae . Mol Microbiol 30:647–656 [CrossRef]
    [Google Scholar]
  8. Finne J., Leinonen M., Mäkelä P. H. 1983; Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355–357
    [Google Scholar]
  9. Frasch C. E., Zollinger W. D., Poolman J. T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504–510 [CrossRef]
    [Google Scholar]
  10. Harrison L. H. 2006; Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 19:142–164 [CrossRef]
    [Google Scholar]
  11. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
    [Google Scholar]
  12. Lemos A. P. S., Brandao A. P., Gorla M. C. O., Paiva M. V., Simonsen V., Melles C. E. A. 2006; Phenotypic characterization of Neisseria meningitidis strains isolated from invasive disease in Brazil from 1990 to 2001. J Med Microbiol 55:751–757 [CrossRef]
    [Google Scholar]
  13. Maiden M. C., Suker J., McKenna A. J., Bygraves J. A., Feavers I. M. 1991; Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis . Mol Microbiol 5:727–736 [CrossRef]
    [Google Scholar]
  14. Mocca L. F., Frasch C. E. 1982; Sodium dodecyl sulfate-polyacrylamide gel typing system for characterization of Neisseria meningitidis isolates. J Clin Microbiol 16:240–244
    [Google Scholar]
  15. O'Hallahan J., Lennon D., Oster P. 2004; The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 23:S293–S298
    [Google Scholar]
  16. Peeters C. C., Rümke H. C., Sundermann L. C., Rouppe van der Voort E. M., Meulenbelt J., Schuller M., Kuipers A. J., van der Ley P., Poolman J. T. 1996; Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14:1009–1015 [CrossRef]
    [Google Scholar]
  17. Pollard A. J., Moxon E. R. 2002; The meningococcus tamed?. Arch Dis Child 87:13–17 [CrossRef]
    [Google Scholar]
  18. Rosenqvist E., Hoiby E. A., Wedege E., Bryn K., Kolberg J., Klem A., Ronnild E., Bjune G., Nokleby H. 1995; Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63:4642–4652
    [Google Scholar]
  19. Russell J. E., Jolley K. A., Feavers I. M., Maiden M. C., Sukert J. 2004; PorA variable regions of Neisseria meningitidis . Emerg Infect Dis 10:674–678 [CrossRef]
    [Google Scholar]
  20. Sacchi C. T., Lemos A. P., Brandt M. E., Withey A. M., Melles C. E. A., Solari C. A., Frasch C. E., Mayer L. W. 1998; Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5:845–855
    [Google Scholar]
  21. Sacchi C. T., Withey A. M., Popovic T., Beall D. S., Reeves M. W., Plikaytis B. D., Rosenstein N. E., Perkins B. A., Tondella M. L., Mayer L. W. 2000; Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis 182:1169–1176 [CrossRef]
    [Google Scholar]
  22. Sacchi C. T., Lemos A. P., Popovic T., de Morais J. C., Whitney A. M., Melles C. E. A., Brondi L. M. G., Monteiro L. M. C., Paiva M. V. other authors 2001; Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997–1998. Overview and implications for vaccine development. J Clin Microbiol 39:2897–2903 [CrossRef]
    [Google Scholar]
  23. Sánchez S., Abel A., Arenas J., Criado M. T., Ferreirós C. M. 2005; Cross-linking analysis of antigenic outer membrane protein complex of Neisseria meningitidis . Res Microbiol 157:136–142
    [Google Scholar]
  24. Taha M. K., Alonso J. M. 2007; Meningococcal vaccines: to eradicate the disease, not the bacterium. Hum Vaccin 3:149–152 [CrossRef]
    [Google Scholar]
  25. van der Ende A., Hopman C. T., Zaat S., Essink B. B., Berkhout B., Dankert J. 1995; Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between −10 and −35 regions of the promoter. J Bacteriol 177:2475–2480
    [Google Scholar]
  26. van der Ende A., Hopman C. T. P., Dankert J. 1999; Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis . Infect Immun 67:2928–2934
    [Google Scholar]
  27. van der Ley P., Heckles J. E., Virji M., Hoogerhout P., Poolman J. T. 1991; Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59:2963–2971
    [Google Scholar]
  28. van der Ley P., van der Biezen J., Hohenstein P., Peeters C., Poolman J. T. 1993; Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis . Infect Immun 61:4217–4224
    [Google Scholar]
  29. Vicente D., Esnal O., Michaus L., López de Goicoechea M. J., Cisterna R., Pérez-Trallero E. 2005; Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003. J Med Microbiol 54:381–384 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47631-0
Loading
/content/journal/jmm/10.1099/jmm.0.47631-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error